Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:26:50.011Z.
Calculation as of: 2026-10-06T21:26:50.011Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 451a64ce4da380df6ab4c5027584c6fd3c25ecc0cb3c19eab7daced69cd0f5b9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$32.93M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$34.97M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $33.61M | N/A | N/A | N/A | N/A |
| Scilex Holding Company (SCLX)vs › | $33.63M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | N/A | N/A | N/A | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $32.93M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $34.35M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $32.79M | 16.41x | 31.88x | 41.18x | 41.18x |
| HeartBeam, Inc. (BEAT)vs › | $32.42M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.97M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.52M | N/A | N/A | N/A | N/A |
| Nortech Systems Incorporated (NSYS)vs › | $31.52M | 12.85x | 114.94x | 46.61x | 32.69x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
